Intercept Pharmaceuticals, Inc.
ICPT
ICPT was delisted on the 7th of November, 2023.
139 hedge funds and large institutions have $332M invested in Intercept Pharmaceuticals, Inc. in 2021 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 32 increasing their positions, 51 reducing their positions, and 15 closing their positions.
67% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 15
7% more funds holding
Funds holding: 130 → 139 (+9)
26% less capital invested
Capital invested by funds: $446M → $332M (-$115M)
27% less call options, than puts
Call options by funds: $17M | Put options by funds: $23.2M
37% less repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 51
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$11.2M |
| 2 |
State Street
Boston,
Massachusetts
|
+$7.82M |
| 3 |
EAM
EULAV Asset Management
Sarasota,
Florida
|
+$5.2M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
+$3.85M |
| 5 |
Renaissance Technologies
New York
|
+$3.19M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$14.6M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$8.69M |
| 3 |
Morgan Stanley
New York
|
-$6.43M |
| 4 |
PP
PDT Partners
New York
|
-$2.29M |
| 5 |
Charles Schwab
San Francisco,
California
|
-$1.86M |
ICPT Hedge Fund Activity: Q3 2021 in Review
139 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Intercept Pharmaceuticals, Inc. (ICPT) for Q3 2021, worth a combined $332M — down 26% from $446M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new ICPT positions and 15 closed out — a net gain of 10 holders — while 32 added to existing stakes and 51 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $11.2M. The largest seller was JP Morgan Chase, cutting an estimated $14.6M.
- 139 institutional investors held Intercept Pharmaceuticals, Inc. (ICPT) as of Q3 2021, up from 130 in Q2 2021.
- Funds reported $332M of Intercept Pharmaceuticals, Inc. stock for Q3 2021, down 26% quarter-over-quarter.
- 25 funds opened new Intercept Pharmaceuticals, Inc. positions in Q3 2021 and 15 closed out, a net change of +10 holders.
- The largest Intercept Pharmaceuticals, Inc. buyer in Q3 2021 was Point72 Asset Management, an estimated $11.2M added.
- The largest Intercept Pharmaceuticals, Inc. seller in Q3 2021 was JP Morgan Chase, an estimated $14.6M sold.
Based on aggregated 13F filings for Q3 2021.